Skip to main content
TipRanks
Go Ultimate75% OFF

Hemostemix (HEM) AI Stock Analysis

21 Followers
TSE:HEM

Hemostemix

(TSXV:HEM)

Select Model
Rating:37Underperform
Price Target:CAD 0.03â–¼(-5.71% Downside)
Action:reiterated
Date:11/17/26

The overall score is at the absolute minimum of 37, driven by a complete absence of revenue, insolvent balance sheet, and accelerating cash burn. Technicals confirm a persistent downtrend with deeply bearish momentum, while negative earnings render traditional valuation metrics useless. The company faces extreme financial risk with no mitigating factors from earnings calls or corporate events.

Positive Factors
Regenerative medicine focusA focused regenerative-medicine strategy gives Hemostemix a defined platform and therapeutic objective rather than a broad, unfocused pipeline. If clinical and regulatory work succeeds, patient-derived therapies could support differentiated applications in serious vascular diseases over the medium term.
Negative Factors
Pre-commercial revenue profilePersistent absence of revenue confirms that Hemostemix has not yet established commercial product sales or operating leverage. Until a program reaches commercialization, research and regulatory spending must be supported externally, leaving results highly dependent on clinical progress and future financing.

Hemostemix (HEM) vs. iShares MSCI Canada ETF (EWC)

-60%-40%-20%0%20%40%TSE:HEM-56.25%EWC+18.67%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 7.40M
Dividend Yield
―
Average Volume (3M)
42.58K
Price to Earnings (P/E)
-1.2
Beta (1Y)
0.56
Revenue Growth
―
EPS Growth
16.04%
Country
Canada
Employees
12
Sector
General
Sector Strength
55
Industry
Biotechnology

Hemostemix Business Overview & Revenue Model

Company Description

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment...

Hemostemix Financial Statement Overview

Summary

Hemostemix exhibits severe financial distress with zero revenue, escalating net losses, negative stockholders' equity, and rapidly deteriorating cash flow. The company is insolvent and entirely dependent on external financing, reflecting the lowest possible financial health.

Income Statement

1Very Negative

Balance Sheet

1Very Negative

Cash Flow

1Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue000000
Gross Profit-33-46-100-223-495-1,101
EBITDA-4.30M-4.26M-1.98M-1.95M-4.39M-6.45M
Net Income-4.54M-4.71M-2.62M-2.50M-5.24M-6.29M
Balance Sheet
Total Assets257.07K846.90K991.86K313.76K465.35K563.05K
Cash, Cash Equivalents and Short-Term Investments196.46K741.72K705.70K155.42K135.75K219.44K
Total Debt3.56M3.60M4.94M4.32M4.13M1.48M
Total Liabilities6.02M5.82M8.20M7.68M7.23M5.85M
Stockholders Equity-5.76M-4.97M-7.20M-7.37M-6.77M-5.28M
Cash Flow
Free Cash Flow-5.27M-4.53M-1.90M-1.42M-6.10M-3.48M
Operating Cash Flow-5.27M-4.53M-1.90M-1.42M-6.10M-3.48M
Investing Cash Flow-304-145.88K000171.12K
Financing Cash Flow4.73M4.66M2.45M1.44M6.02M3.27M

Hemostemix Technical Analysis

Technical Analysis SentimentNegative
Last Price0.04

Price Trends

50DMA0.06Negative
100DMA0.06Negative
200DMA0.07Negative

Market Momentum

MACD-0.00Positive
RSI27.27Positive
STOCH41.11Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HEM, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.06, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 27.27 is Positive, neither overbought nor oversold. The STOCH value of 41.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:HEM.

Hemostemix Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TSE:HEM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TSE:BLABTSE:BLAB52NeutralCAD 11.36M0.76101.66%―――
TSE:PREVTSE:PREV45NeutralCAD 15.95M-20.8310.15%――-36.36%
TSE:HEMTSE:HEM37UnderperformCAD 7.40M-1.2192.37%――16.04%

* General Sector Average

Performance Comparison

-50%0%50%TSE:HEMTSE:IOTTSE:BLABTSE:PREVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:HEM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:HEMHemostemix Inc0.04-0.05-58.82%
TSE:IOTInnovotech Inc0.09-0.13-58.72%
TSE:BLABBritannia Life Sciences Inc0.07-0.02-26.32%
TSE:PREVPreveCeutical Medical 0.030.000.00%

Hemostemix Corporate Events

Business Operations and StrategyPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance

Hemostemix Wins Bahamas Approval for VesCell Trial and Advances Financing, Manufacturing

Positive
Oct 8, 2026

Hemostemix has secured full approval from The Bahamas’ National Longevity and Regenerative Therapy Board, including ethics clearance, to run a commercial Phase 1 study of its VesCell therapy for angina, vascular dementia and pain, strengthening its p...

Business Operations and StrategyPrivate Placements and Financing

Hemostemix Advances $1 Million Private Placement to Fund Stem Cell Therapy Commercialization

Positive
Sep 24, 2026

Hemostemix Inc. has moved to secure price protection as it prepares to close the third tranche of a previously announced non‑brokered private placement, aiming to raise $1 million through units comprising common shares and warrants listed on the TSX...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026